CClinicalTrials.gg
CompletedNCT06900569Updated Feb 23, 2026

Ashwagandha Supplementation for Prevention of Muscle Damage

An interventional study of Ashwagandha and Placebo in Muscle Damage, sponsored by University of Saskatchewan. Completed at 1 site in Canada. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by University of Saskatchewan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Ashwagandha is an herbal supplement that has a wide range of benefits related to exercise when supplemented for about 8-12 weeks. This study aims to investigate whether short-term Ashwagandha supplementation can enhance muscle recovery following exercise by measuring muscle strength recovery, swelling, and soreness in the biceps.

Read the detailed description

The purpose of the study is to determine the effects of Ashwagandha supplementation on recovery from muscle-damaging exercise. Ten to twenty participants will be randomized to receive Ashwagandha supplementation (600 mg/d) or placebo for 10 days. On day 7, participants will perform a muscle damaging exercise session (six sets of concentric and emphasized eccentric repetitions with the biceps). Before and after exercise and at 24, 48, and 72 hours after exercise, isometric muscle strength, muscle swelling (ultrasound), and muscle soreness will be assessed. The investigators hypothesize the Ashwagandha will alleviate symptoms of muscle damage (swelling and soreness) and enhance strength recovery after a bout of muscle-damaging exercise.

02

Conditions studied

  • Muscle Damage
03

In context

Lead sponsor

University of Saskatchewan is the lead sponsor of 237 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: male or female, aged 18-35y

-

Exclusion Criteria:

Conditions that may be affected by exercise (determined by "yes" answers to the "Get Active Questionnaire") Pregnant Breastfeeding

Allergies to:

  • Dicalcium Phosphate
  • Cellulose
  • Vegetable magnesium stearate
  • Silica
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    600 mg/d placebo for 10 days

    Dietary Supplement: Placebo

  • Experimental
    Ashwagandha

    600 mg/d Ashwagandha

    Dietary Supplement: Ashwagandha

Interventions

  • Dietary supplementAshwagandha

    600 mg/d Ashwagandha

  • Dietary supplementPlacebo

    600 mg/d placebo

06

What researchers measure

Primary outcomes

  1. Change in isometric biceps strength measured with a dynamometer (Nm)

    Time frame: 72 hours

Secondary outcomes

  1. Change in muscle thickness measured with ultrasound (cm)

    Time frame: 72 hours

  2. Change in muscle soreness measured with a visual analog scale with scores ranging from 0 (no soreness) to 10 (maximal soreness)

    Time frame: 72 hours

  3. Change in sleep quality with the Pittsburgh Sleep Quality Index with scores ranging from 0 (no sleep problems) to 3 (lowest sleep quality)

    Time frame: 10 days

07

Study locations

1 site
  • University of Saskatchewan
    Saskatoon, Saskatchewan S7K 2X2, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06900569
Lead sponsor
University of Saskatchewan
Responsible party
Phil Chilibeck (Professor, University of Saskatchewan) — Principal investigator
First posted
Mar 28, 2025
Start date
Mar 22, 2025
Primary completion
Apr 30, 2025
Completion
May 15, 2025
Last update
Feb 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion